Resolutions of Eevia Health Plc's Annual General Meeting 2021

The Annual General Meeting of shareholders of Eevia Health Plc was held in Seinäjoki, on June 22, 2021. Two shareholders representing 3 797 500 shares and votes (36,14% of total shares) were represented at the meeting. The AGM decided each and all the proposals from the Board of Directors as described in the Notice of Annual General Meeting, unanimously.

1. Adoption of financial statements for 2020

The AGM approved the financial statements for 2020.

2. Measures for the profit or loss noted in the confirmed balance sheet give rise to

The AGM resolved the net loss of EUR -1 023 378,64 to be transferred to retained earnings / loss account and that no dividend be paid.

3. Discharge from liability of the Board and Chief Executive Officer

The AGM discharged the members of the Board and the CEO from liability.

4. Election of Board members and remuneration to the Board

The AGM resolved to re-elect current Board members, Martin Bjørklund, Per Benjaminsen, Magne Ruus Simensen and Johanna Panula as members of the Board of Directors of Eevia Health Plc. Their term of office will continue until the next Annual General Meeting as stipulated in the Articles of Association.

The AGM approved the following remuneration to the Board:

Chairman:              20.000 € for the period until AGM in year 2022

Members:             10.000 € for the period until AGM in year 2022

The AGM also confirmed the compensation to the current chairman as being for a full term since the AGM of 2020 equaling EUR 20.000 considering the workload last six to nine months.

5. Appointment of the auditor and remuneration

The AGM re-elected PricewaterhouseCoopers Oy as the auditor of the company and Riitta Ulvinen as the principal auditor.

The AGM resolved that the auditor's fees shall be paid according to the auditor's reasonable invoice approved by the company.

6. Listing of the company's shares for trading on Spotlight Stock Market multilateral trading facility and authorizing the Board of Directors to make the decisions related thereto

The Board of Directors has applied for trading of the company's shares on Spotlight Stock Market multilateral trading facility ("Listing") and the Listing application has been approved by Spotlight.

The Annual General Meeting confirmed the Listing and authorized the Board of Directors to make all decisions related thereto. Based on this authorization, the Board of Directors would also be entitled to cancel the Listing.

7. Authorization for the Board of Directors to issue options as part of Incentive program to key employees/managers

The Annual General Meeting resolved to authorize the Board of Directors to decide, in one or more transactions, on the issuance of options to employees and other key persons of the company as follows:

The number of new shares that can be issued based on options may in total amount to a maximum of 706 000 shares or 5% of the outstanding shares after the share issue carried out prior to the listing on Spotlight Stock Market.

The Board of Directors was authorized to decide on all the terms and conditions of the issuances of options. However, an outline of the program is to issue approx. 262 500 options to current key employees with an average exercise price 60% above the share price in the planned IPO round.

To get the options, employees will enter an option agreement with the company with typical clauses, such as terms for "good leaver"/"bad leaver clauses", etc.

The authorization is valid until 31st of May 2023.

8. Establishment of Shareholder' Nomination Board

The AGM resolved to establish a Nomination Board in accordance with corporate governance rules and recommendations for listed companies in Finland. The purpose is to professionalize the audit and election of Board members.

The Shareholders' Nomination Board shall consist of four (4) members, three of which shall be appointed by the company's three largest shareholders, who shall appoint one member each. The Chair of the company's Board of Directors shall serve as the fourth member. The company's largest shareholders entitled to elect members to the Shareholders' Nomination Board shall be annually determined based on the registered holdings in the company's list of shareholders held by Euroclear Finland Oy and Euroclear Sweden AB as of the first weekday in September in the year concerned. 

The Chair of the company's Board of Directors shall request each of the three largest shareholders established on this basis to nominate one member to the Shareholders' Nomination Board. If a shareholder does not wish to exercise his or her right to appoint a representative, the right shall pass to the next-largest shareholder who would not otherwise be entitled to appoint a member. 

The process for electing the members and the Chair of the Shareholders' Nomination Board, as well as the composition and the duties of the Nomination Board will be specified, in more detail, in the Charter adopted for the Nomination Board. The Board is authorized to set the Charter for the coming period.

9. Change of the Articles of Association

The Annual General Meeting resolved that the following addition is made to §8 in the company's Articles of association: "Bolagstämman kan hållas, förutom på bolagets hemort, också i Seinäjoi i Finland". The paragraph is stated in full below.

§8 Deltagande

Aktieägare som önskar delta i bolagsstämma skall anmäla sig hos bolaget senast på i kallelsen till stämman nämnd dag som får infalla tidigast 10 dagar före stämman. Endast aktieägare som åtta vardagar före bolagsstämman (bolagsstämmans avstämningsdag) är införda i aktieägar-förteckningen, har rätt att delta i bolagsstämman. Bolagstämman kan hållas förutom på bolagets hemort, också i Seinäjoki i Finland.

For more information, please contact: 

Kim Nurmi-Aro, CFO

[email protected]

Tel.: +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. The Company addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts, which have scientifically documented health benefits, are sold B2B as ingredients to dietary supplements and food brands globally.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Nerladdningsbara filer

Eevia Health appoints new distributor

Eevia Health Plc, ("Eevia" or "The Company") has appointed Select Ingredients, San Diego, California, USA, as new distributor in the territory of the USA.


Gabriella Beni joins Eevia Health Plc as the new Chief Financial Officer

Eevia Health Plc ("Eevia" or "The Company") is welcoming Gabriella Beni as our new Chief Financial Officer. Kim Nurmi-Aro will leave the Company on March 16th and the Company wishes him the very best in his new professional endeavors close to his home in the city of Vaasa. Gabriella Beni will take over the position on March 17th.


Eevia Health lands a new sales agreement for specialty plant-based nutraceutical extract worth SEK 8 million.

Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market.


Eevia Health Plc Interim Report Quarter 4 - 2021

Significant events during the fourth quarter and full-year 2021:

  • Net sales for the year grew by over 130% compared to 2020, amounting to the total revenue of KEUR 6,671.
  • During Q4, 2021 Net sales amounted to KEUR 658 compared to KEUR 1,534 in 2020. The underlying Net Sales in Q4, 2021 was KEUR 801. The underlying revenue was higher than the reported revenue. Eevia credited one sold batch in Q4-21 that needed reprocessing. Eevia will resell the batch in Q1-22.
  • EBITDA for Q4, 2021 came in at KEUR -811 (KEUR -409).
  • Eevia added several new prospects to the pipeline during the period, and the Company has ongoing negotiations for long-term contracts.
  • The order reserve increased in Q4-21. As previously communicated, among new orders were:
  • an MSEK 3,4 / MEUR 0,34 sales order for highly concentrated bilberry extract (Feno-Myrtillus® 36 Organic).
  • New sales orders for organic pine bark extract (Fenoprolic® 70 Organic).
  • A human clinical study concluded on Feno-Chaga® Organic was completed with positive results, Scientific documentation of the efficacy of Eevia's plant extracts is a crucial factor in growing customer interest and sales of Eevia's products.
  • Eevia Health successfully completed an equity issue with proceeds of KEUR 1,903 in Q4-21.
  • Eevia made a significant drive in Q4-21 to become a leader in environmental sustainability and occupational safety. We launched several new actions to reduce emissions and strengthen our sustainability. The initiative included testing various technologies, such as reversed osmosis, nanofiltration, and ultrafiltration. The target is to minimize emissions of organic compounds to air and wastewater. Reducing emissions is the right thing for the environment and supports our brand as the most sustainable extracts producer.


Harri Salo joins Eevia Health Plc as Chief Manufacturing Officer to strengthen top management competence and capacity

Eevia Health Plc, ("Eevia" or "The Company"), is welcoming Harri Salo as our new Chief Manufacturing Officer. Harri Salo has a 15-year strong career in operations and production management in international industrial business environments. He will start Monday, January 10th, and significantly strengthen Eevia Health's management capacity and competence for developing production organization, operation, and business processes.


Eevia Health Plc receives 3,4 MSEK/0,34 MEUR sales order for bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a large sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

The sales value of this order is c.335,000 EUR and the product is Feno-Myrtillus 25 bilberry extract. The order is expected to create repeat sales of this product going forward.





Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted